Kenta Biotech Includes First Patient in its First-in-Human Trial of Promising Monoclonal Antibody KBSA301

Kenta Biotech has announced an important step towards a more efficient treatment of hospital infections: The first patient was enrolled in the phase I/II clinical trial with KBSA301, a fully human antibody for the treatment of severe pneumonia caused by Staphylococcus aureus (S. aureus).

In this clinical trial, 44 patients suffering from severe pneumonia caused by S. aureus admitted in intensive care units around Europe will be administered a single dose of KBSA301, or placebo, in addition to standard antibiotic therapy.

KBSA301 is developed by Kenta Biotech as a new treatment option to fight severe S. aureus infections, including those caused by antibiotic resistant strains.

Founded six years ago, Swiss biotech start-up Kenta is a leader in the field of antibody treatment in nosocomial infections.

In the field of infectious diseases, this is one of the few therapeutic monoclonal antibodies that is tested in a first-in-human trial directly in patients.

Kenta Biotech, in this way, can accelerate the clinical development and bringing this new compound faster to patients.

Novel approach for treatment of infections

KBSA301 binds to Staphylococcal alpha-toxin, thus preventing the toxin from damaging the lungs of the patients. Its mode of action is independent from the antibiotic resistance profile of S. aureus, therefore covering both MRSA (methicillin-resistant S. aureus) and MSSA (methicillin-sensitive S. aureus).

This constitutes a significant progress in the treatment of severe S. aureus infections. The therapeutic activity of KBSA301 demonstrated in preclinical animal studies resulted in a significant survival benefit for treated animals.

This, along with an excellent safety profile enabled Kenta Biotech to obtain permission from health authorities in four major countries to test the antibody on intensive care unit patients with severe S. aureus pneumonia.

Franco Merckling, CEO said: “This is a great day for patients, for doctors and for Kenta Biotech. Thanks to intensive research and the dedication of our outstanding staff, we are able to bring a human monoclonal antibody with an innovative mode of action into clinical development in record time. I am confident that this trial will deliver promising data and pave the way for change in the treatment of severe S. aureus pneumonia.”

Toni Perez, Chief Medical Officer said: “We are very excited about this clinical trial. For more than 25 years, I have been developing new anti-infective drugs, and I have never seen a drug with such tremendous potential. Patients and doctors have been eagerly waiting for a solution like the one to be expected from KBSA301.”

RELATED ARTICLES

The microfluidic device with interlinking modules containing human-derived heart, liver, skeletal muscle and nervous system cells was able to maintain cellular viability and record cellular function in real-time for 28 days.

An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.